Moderna and Merck Announce Positive Late-Stage Trial Results for mRNA Cancer Therapy
Shares of Merck (MRK) and Moderna (MRNA) rose in premarket trading after the companies announced that their jointly developed mRNA-based cancer therapy, intismeran autogene, successfully completed a late-stage trial. The treatment showed positive results for patients with melanoma, an aggressive form of skin cancer. The success marks a significant milestone in the development and application of mRNA technology beyond vaccines into oncology treatments. Both companies are now likely to advance toward regulatory submissions or further clinical trials based on these findings. This breakthrough could expand the market potential for both firms as they explore new therapeutic applications using their core mRNA platform, potentially attracting investor interest.
Topics: biotech cancer_therapy melanoma mRNA_technology